clinical trial · NCT07945821
A Study of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors
Solid TumorTagmokitugPasritamig
brief summary
The primary purpose of this study is to evaluate the safety and tolerability of tagmokitug in combination with other therapies.
started
Nov 1, 2026
primary completion
Aug 1, 2028
completion
Aug 1, 2028
last updated
Nov 18, 2026
official title
A Phase 1/2, Multicenter, Open-Label, Multicohort Study Evaluating the Safety and Efficacy of Tagmokitug in Combination With Other Treatments in Participants With Advanced or Metastatic Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol